Join to View Full Profile
1725 W Harrison StSte 1010Chicago, IL 60612
Phone+1 312-942-5904
Fax+1 312-942-3194
Dr. Ustun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2005 - 2006
ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2002 - 2005- Medical College of GeorgiaFellowship, Hematology and Medical Oncology, 2000 - 2002
Ankara University FOMClass of 1990
Certifications & Licensure
IL State Medical License 2018 - 2026
IN State Medical License 2023 - 2023
MN State Medical License 2010 - 2019
GA State Medical License 2005 - 2011
NC State Medical License 2002 - 2006
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT Start of enrollment: 2017 Apr 12
Publications & Presentations
PubMed
- Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.Jason Gotlib, Andreas Reiter, Deepti H Radia, Iván Álvarez-Twose, Michael W Deininger
Blood Advances. 2026-01-28 - 1 citationsAllogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR study.Celalettin Ustun, Mei-Jie Zhang, Andrew Peterson, Alexander Baek, Mounzer Agha
British Journal of Haematology. 2025-12-01 - 2 citationsImpact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh
Blood Advances. 2025-10-28
Journal Articles
- Diffuse Alveolar Hemorrhage Is Most Often Fatal and Is Affected by Graft Source, Conditioning Regiment Toxicity, and Engraftment KineticsErhan H Dincer, Erica D Warlick, Margaret L MacMillan, Patrick Arndt, Daniel J Weisdorf, Nelli Bejanyan, Claudio G Brunstein, Celalettin Ustun, Aleksandr Lazaryan, Ver..., Haematologica
Lectures
- Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
'It Really Sets Us Apart'September 11th, 2025- Higher Stakes in Systemic MastocytosisJune 18th, 2021
Nonmyeloablative Conditioning Carries Lowers Infection Risk in Patients with AMLSeptember 10th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
